Finance

Lists
249420:KRX
Il Dong Pharmaceutical Co Ltd
â‚©15,030.00
-0.46%
(-70.00) 1D
Sep 4, 3:30:30 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 249420...
Open
â‚©15,010
High
â‚©15,280
Low
â‚©14,700
Mkt. cap
475.52B
Avg. vol.
368.46K
Volume
512.61K
Dividend
1.33%
Quarterly dividend
â‚©50
Ex-dividend date
Mar 30, 2026
P/E ratio
10.62
52-wk high
â‚©45,050
52-wk low
â‚©11,250
EPS
â‚©1,415
Shares outstanding
31.64M
No. of employees
1K
Open
â‚©15,010
High
â‚©15,280
Low
â‚©14,700
Mkt. cap
475.52B
Avg. vol.
368.46K
Volume
512.61K
Dividend
1.33%
Quarterly dividend
â‚©50
Ex-dividend date
Mar 30, 2026
P/E ratio
10.62
52-wk high
â‚©45,050
52-wk low
â‚©11,250
EPS
â‚©1,415
Shares outstanding
31.64M
No. of employees
1K
About Il Dong Pharmaceutical Co Ltd
CEOWung Seop Yoon
Employees1.05K
Founded1941
Headquarters-
SectorPharmaceutical industry
Websiteildong.com
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
145.46B
147.02B
142.00B
147.86B
Cost of goods sold
86.98B
90.12B
83.46B
91.24B
Cost of revenue
86.98B
90.12B
83.46B
91.24B
Research and development expenses
9.38B
9.15B
9.06B
10.55B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
40.49B
38.46B
38.99B
42.93B
Operating expense
51.72B
51.15B
49.13B
53.00B
Total operating expenses
138.70B
141.27B
132.59B
144.24B
Operating income
6.76B
5.75B
9.41B
3.62B
Other non operating income
16.98B
2.25B
493.34M
313.42M
EBT including unusual items
28.30B
6.09B
9.20B
3.46B
EBT excluding unusual items
21.28B
6.09B
8.16B
2.74B
Income tax expense
6.81B
489.84M
1.82B
-1.64B
Effective tax rate
24.07%
8.04%
19.79%
-47.36%
Other operating expenses
446.84M
249.24M
261.46M
207.71M
Net income
22.41B
7.24B
8.27B
5.70B
Net profit margin
15.40%
4.92%
5.82%
3.85%
Earnings per share
-
-
-
-
Interest and investment income
172.88M
102.81M
109.44M
231.08M
Interest expense
-2.77B
-1.93B
-1.82B
-1.81B
Net interest expenses
-2.60B
-1.82B
-1.71B
-1.58B
Depreciation and amortization charges
1.25B
1.20B
1.07B
1.08B
EBITDA
12.46B
11.08B
14.91B
9.15B
Gain or loss from assets sale
140.84M
3.66M
10.12M
753.47M
AI content may include mistakes. Learn more
Google apps